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Abstract 
Background: The aim of the present investigation was to evaluate the literature recurrence of peripheral giant cell 
granuloma and pyogenic granuloma associated with dental implants. It’s important to know the characteristics pre‑
sent in these lesions and possible effects on the prognosis of dental implants.
Methods: An electronic search without time restrictions was done in the databases: PubMed/Medline. With the 
keywords "Granuloma" OR "Granuloma, Giant Cell" OR "peripheral giant cell" OR "Granuloma, Pyogenic” AND "Dental 
implants" OR "Oral implants”.
Results: After applying the inclusion and exclusion criteria, a total of 20 articles were included, which reported 32 
lesions (10 pyogenic granulomas, 21 peripheral giant cell granulomas and one peripheral giant cell granuloma com‑
bined with peripheral ossifying fibroma, all associated with implants). According to our review, these lesions are more 
frequent in males and in the posterior region of the mandible. Both excision and curettage of the lesion, compared to 
only excision, presented similar recurrences (40%). Explantation of the implant was performed in 41% of cases without 
additional recurrences. The results are not statistically significant when comparing one lesion to the other in terms of 
explantation (p = 0.97), recurrence (p = 0.57) or bone loss (p = 0.67).
Conclusions: The main therapeutic approach is tissue excision. The lesions show a high recurrence rate (34.4%), 
which often requires explantation of the associated implant. This recurrence rate is not affected by curettage after 
excision.
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Background
The replacement of missing teeth with dental implants 
has a high success rate, but it is still a technique which 
involves risks and requires good evaluation and planning 
to minimize failures [1, 2]. However, the increasing num-
ber of dental implants used leads the dentist to encounter 
biological and technical complications [3, 4]. The most 
prominent biological complications are peri-implant 
mucositis and peri-implantitis [3, 5, 6]. In a 2017 system-
atic review, Lee et al. [7] demonstrated that the rates of 
mucositis and peri-implantitis were 29.48% and 9.25%, 
respectively.
The appearance of so-called peri-implant reactive 
lesions is another complication that must be taken into 
consideration. Despite its lower incidence, its presence 
could imply the need for explantation [2, 3, 8]. Reactive 
lesions are characterized by excessive proliferation of 
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connective tissue in response to chronic irritation [9]. 
Among these lesions, those most frequently observed in 
the oral cavity are pyogenic granuloma (PG), traumatic 
fibroma, fibroepithelial hyperplasia, peripheral ossifying 
fibroma and peripheral giant cell granuloma (periheral 
giant cell lesion, -PGCG-) [4, 9]. PG and PGCG are the 
reactive lesions most frequently associated with teeth and 
implants [2, 9]. Some factors such as chronic inflamma-
tion, the accumulation of foreign bodies or corrosion of 
the implant surface could cause a chronic irritative pro-
cess and act as contributing factors not only for mucositis 
and peri-implantitis but also for PG and PGCG [3, 4, 10].
Several factors have been studied that could interfere 
with osseointegration and therefore the survival of the 
placed implant. Factors such as smoking, diabetes and 
periodontal disease have been studied [9, 11]. However, 
with regard to reactive lesions, such as PG and PGCG, 
the prevention technique is the maintenance of healthy 
peri-implant tissue [9] (Fig. 1).
PG can occur in response to irritants, trauma, hormo-
nal changes or certain medications. Although classically 
called PG, the most correct name would be capillary 
lobular hemangioma, since the lesion is not strictly a 
granuloma or an infection [9, 10]. Clinically, oral PG is 
characterized as an exophytic mass with a smooth or 
lobulated appearance that can be sessile or peduncu-
lated. The epithelium is frequently ulcerated and varies 
in color from pink to red and/or purple, depending on 
the evolution time and the vascularization of the lesion. 
The lesion tends to grow rapidly in a short period of time, 
with a tendency to bleed spontaneously or after a minor 
trauma [10, 12]. Its incidence varies between 3.81 to 7% 
of the histopathological results of biopsies performed 
in the oral cavity [3, 12]. According to the literature, it 
is more frequent in young women (3:2), more common 
in the maxilla than in the mandible, and in the anterior 
areas when associated with teeth [9]. Histologically, PG is 
composed of proliferating blood vessels and granulation 
tissue, often organized in lobular aggregates, hence the 
name capillary lobular hemangioma [3]. It is character-
ized by prominent capillary growth in hyperplastic gran-
ulation tissue, suggesting high angiogenic activity. Blood 
vessels often show a grouped or separated pattern by less 
vascular fibrotic septa, leading some authors to consider 
PG as a polypoid form of capillary hemangioma [12].
PGCG is believed that its pathogenesis includes an 
excessive activation of osteoclasts, which is associated 
with a proliferation of macrophages and can cause sig-
nificant bone resorption [9]. Clinically, PGCG may pre-
sent as a firm or soft, sessile or pedunculated nodule, 
color ranging from bluish to purple, with a frequently 
ulcerated surface, confined to the alveolar and/or gingival 
mucosa. Swelling is the most frequent sign and its clinical 
course is usually asymptomatic [4, 13]. It tends to show 
a progressive increase in size and can cause pressure on 
the adjacent teeth, which could lead to malocclusion or 
interference with mastication. Erosion of the underlying 
bone or periodontium can also occur and in edentulous 
areas, it can often cause a radiolucent cup-shaped image 
in intraoral radiography [4]. PGCG does not have an age 
predilection. It seems to have a greater predilection in 
women and tends to appear more frequently in the molar 
area [4, 9, 11]. It consists of a non-encapsulated lobulated 
tumor of proliferating vascular connective tissue with a 
large number of osteoclast-type multinucleated giant 
cells. It is common to find signs of bleeding and hemosi-
derin deposits inside the lesion. Fibroblastic proliferation 
and/or significant formation of osteoid material and even 
bone is common. Blood biochemistry shows no altera-
tions [3, 13]; however, if alteration of phosphorus-cal-
cium metabolism appears, hyperparathyroidism should 
be suspected and a brown parathyroid tumor should be 
ruled out [14–16].
The treatment of both PG and PGCG includes com-
plete surgical excision until bone level and complete 
curettage, as well as removal of the causative agent if 
identified [17]. Since it is rarely reported it’s important to 
know the characteristics present in these lesions and pos-
sible effects on the prognosis of dental implants in order 
to take the appropriate course of action in the clinical 
practice.
The aim of the present study was to search the associa-
tion of the available data published in the literature on 
PG and PGCG associated with dental implants, analyzing 
their recurrences, associated etiological factors and dif-
ferent treatment options. For this we asked ourselves the 
following PICO question: What is the prevalence, recur-
rence, etiological factors and treatment of PG and PGCG Fig. 1 Pyogenic granuloma associated with a dental implant
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around dental implants? P: Dental implants; I: develop-
ment of a reactive lesion; C: PG vs. PGCG, type of treat-
ment carried out (excision vs. excision and curettage); 
O: Prevalence of PG and PGCG around dental implants, 
recurrence of the lesions and bone loss around dental 
implants associated with the lesions.
Methods
Search strategy
The present study followed the Preferred Reporting Items 
for Systematic Reviews and Meta-Analysis (PRISMA) 
guidelines [18]. An electronic search was conducted in 
February 2020, with no time restrictions in the database: 
PubMed/Medline. The following terms were used for the 
search strategies: ["Granuloma" OR "peripheral giant cell 
granuloma" OR "Granuloma, Giant Cell" OR "peripheral 
giant cell" OR "Granuloma, Pyogenic" OR "peripheral 
giant cell reparative granuloma” OR "peripheral giant cell 
epulis”] AND ["Dental implants" OR "Oral implants”].
Article selection and inclusion criteria
The inclusion criteria were publications on cases of PG 
and PGCG associated with dental implants, with suf-
ficient clinical, radiological and histological information 
to confirm the diagnosis (at least 8 out of the 10 out-
comes of the table should be included); case series and 
single case studies. Articles that were written in English 
or Spanish. Articles with other lesions or syndromic con-
ditions with similar characteristics, review, book chapter 
and letter to the editors were excluded.
Data extraction and analysis
For each of the included studies, the following data were 
extracted (whenever available): age, sex, location of the 
lesion, implants involved, presence of bone loss, time 
between implant placement and the appearance of the 
lesion, treatment performed, recurrence, implant failure 
and possible associated pathologies observed. Regard-
ing bone loss, we made a subjective assessment; classi-
fying severe as exposure of more than 3 implant threads 
or bone loss of ≥ 4 mm, moderate to less than 3 exposed 
threads (between 3–4 mm) and mild as a loss of less than 
3 mm of bone based on radiographs and intraoral photo-
graphs or on the authors’ criteria.
All cases are initially selected and analysed by NRQ & 
BGN, discrepancies are consulted with EJS, KIG & AMR 
and in case of doubt they are finally validated by AED 
and JLL.
All statistical analyses were conducted using Statistical 
Package for the Social Sciences (SPSS 12.0, Chicago, IL). 
Mean values of age and time of diagnosis of the lesions 
were estimated. Fisher’s exact test was used to analyze 
recurrence of lesions and bone loss. All reported values 
(P values) were compared to a significance level of 5%.
Results
141 articles were obtained with the search strategy 
used. After excluding duplicate articles, 91 articles were 
selected and reading the title and abstract, 32 were left. 
Out of 32 articles, 4 were excluded because they were not 
written in English or Spanish, 6 due to lack of data and 
2 because data was related to teeth instead of implants. 
Finally, 20 articles that met the inclusion and exclusion 
criteria previously specified were selected (Fig. 2).
The 20 papers analyzed [4, 9, 11, 17, 19–34] reported 
30 patients with 32 lesions around 51 implants involved, 
and 2 patients reported two lesions. Histologically, 10 
lesions were diagnosed as PG [9, 22, 24–26, 28, 30, 31], 
21 as PGCG [4, 9, 11, 17, 19–21, 23, 29, 32–34] and one 
combined PGCG with an ossifying peripheral fibroma 
[24]. The epidemiological and clinical characteristics are 
summarized in Table 1.
Lesions were more prevalent (in this review) in men 
than in women (20:12), more in the mandible than in the 
maxilla, with a mean age of 51 years (range between 21 
and 75 years). Information on the time between implant 
placement surgery and diagnosis of the lesion was avail-
able in 27 lesions with a mean of 3.5 years (range between 
1 month and 12 years) [9, 11, 17, 19–32].
Regarding the first therapeutic approach, excision of 
the lesion was performed in all cases. In 5/32 cases [11, 
20, 23, 27, 32], only the excision of the lesion was per-
formed, presenting two cases of recurrence [20, 23]. In 19 
out of 32 cases [9, 11, 17, 19, 23–25, 29, 31, 33] the treat-
ment was accompanied by curettage of the underlying 
bone, with recurrences in 8 out of 19 cases [11, 17, 23, 31] 
and 6 of these 8 cases finally required explantation [11, 
17, 23, 31] due to this recurrence and bone loss. One case 
[28] was treated using laser technique without recurrence 
and another [30] with electrocautery, which did recur. 
Finally, in the remaining 6 cases [4, 21, 22, 26], excision of 
the lesion was performed in association with the explan-
tation, without later recurrence. Based on these data, we 
can say that of the 13 cases in which explantation was not 
performed, the rate of recurrence of the lesions surgically 
excised with curettage was not significant compared to 
only the removal of the lesion, with a p = 0.97. Due to the 
lack of data, we do not know if the lesions that were only 
eliminated were the smallest. According to these data, 
clinically, we would choose to excise the lesion without 
curettage, avoiding further bone loss and damaging the 
implant surface. However it should be taken into account 
that the patients sample who do not undergo excision 
plus curettage is significantly smaller than those who 
undergo curettage.
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A total of 11 out of 32 (34.4%) lesions [11, 17, 20, 23, 30, 
31] with recurrences were found, of which 4 [11, 23, 31] 
reported more than 3 recurrences, requiring an explanta-
tion to solve the issue. Of these 11 lesions, 9 were diag-
nosed as PGCG [11, 17, 20, 23] and 2 as PG [30, 31]. In 
this review, recurrence rate is not statistically significant 
for one lesion or another, with a p = 0.57.
In 75% of cases [4, 9, 11, 17, 19, 21–24, 28–31, 33, 
34] bone loss was observed (Table  2). 10 cases (41.6%) 
reported severe [4, 11, 17, 21, 22, 29, 31], 9 cases (37.5%) 
reported moderate [9, 11, 19, 28, 30, 31, 33] and 5 cases 
(20.8%) reported mild bone loss [23, 24, 34]. Of the 24 
cases with bone loss, implants involved were explanted in 
45.8% [4, 11, 17, 21–23, 31]; of which 81.8% had severe 
bone loss [4, 11, 17, 21, 22, 29, 31] and 81.8% were PGCG 
[4, 11, 17, 21, 23] (Table 2). 8 cases (out of 32) did not pre-
sent bone loss, comprising of 5 PGCG compared to 3 PG, 
and there was no statistical significance with a p = 0.65. 
If we correlate total severe bone loss [10, of which 8 are 
PGCG and 2 PG] with moderate or mild bone loss [14 of 
which 9 are PGCG and 5 PG], we also do not obtain sig-
nificant results, with a p = 0.4.
The attributed etiopathogenesis is varied (Table  3). In 
71.8% (23 of 32) of the cases, observations that inform 
about a possible etiology were made. 26% (6 of 23) had 
poor oral hygiene, and 50% (3 of 6) required explantation. 
After the correction of these prostheses, there were no 
recurrences, and therefore explantation of the implants 
Fig. 2 PRISMA flowchart
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was not required. In 30% (7 of 23) of the cases, implant 
placement was performed with bone grafting, 57.1% (4 
of 7) required explantation and in 2 of them (with asso-
ciated PG) it is specified that iliac crest grafts were used 
[31], of the other 2, one presented PG and the other 
PGCG. Although in all 7 cases, there could be other 
associated factors, the authors preferred to attribute the 
occurrence to the graft. Finally, in 2 of the 23 cases the 
etiology was supposed to be periodontal disease [9, 11], 
both being PGCG and without explantation. One of the 
cases included in which the prosthesis was the cause 
of the lesion, was not included here because the author 
stated that the most relevant cause was the design of the 
prosthesis [17].
Discussion
PG and PGCG are inflammatory reactive lesions gener-
ally found around teeth, root stumps and dental implants. 
The main feature helping to differentiate PGCG from 
PG is the abundant presence of multinucleated giant 
cells [35]. Although PG is considered more frequent 
than PGCG as a lesion, in this review PGCG is more 
frequently reported than PG in association with dental 
implants, data also supported the study by Brown et  al. 
[20]. Based on this review, implant-associated PG and 
PGCG are rare peri-implant soft tissue complications, 
initially reported by Hirshberg et  al. [23] and as men-
tioned by Peñarrocha-Diago et al. [19], due to few docu-
mented cases, the etiology and incidence of these lesions 
are not well established.
With respect to location, both in our review and in the 
cases reported in the literature, PG and PGCG associ-
ated with implants have a predilection for the poste-
rior regions of the jaws (20:12), mainly in the mandible 
(19:13) [9, 19]. This can be explained by the fact that the 
implants placed in the posterior regions hinder proper 
oral hygiene, which seems to be a factor that favors the 
appearance of these lesions [2, 9]. Although Hernández 


































































































































































































































































































































































































































































































































































































Table 2 Distribution of cases with bone loss
There is no statistical significance
(*) 8 are PGCG and 1 is PG; (#) It is a PG; (&) It is a PGCG; Exp: Explantation; NO 




11 9* 1# 1& Exp
21 1 8 4 8$ No exp
32 10 9 5 8 Total
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the posterior area are also a risk factor for the develop-
ment of reactive lesions around the implants. Or simply 
the fact that more implants are placed in these locations, 
as different authors report while analyzing the literature 
[2, 9, 31].
The literature refers that when these lesions (PG and 
PGCG) affect the peridental areas, they are more fre-
quent in women, although some studies have shown an 
equal prevalence for both sexes [2, 9]. This is in contrast 
with our findings that suggest that when these lesions 
are associated with implants, they are more frequent in 
men (20:12). According to Woelber et al. [36], this finding 
could be due to the fact that men have a higher plaque 
index than women, probably due to a lower level of 
hygiene, however, this is an inconsistent conclusion.
Dental implants are most commonly used in elderly 
patients; therefore, reactive lesions are expected to 
appear in older patients compared to those seen around 
natural teeth [2, 20]. In this review, it was observed that 
the age range was from 21 to 75  years, with an aver-
age age of 51 years, similar to the studies by Atarbashi-
Moghadam et al. [2] with a mean age of 51.28 ± 14.48 and 
Brown et al. [20] with an average age of 50.9 years.
A possible pathogenesis of PG and PGCG associated 
with dental implants is a chronic local irritation that acts 
on the gingival tissue. In this sense, the local irritating 
factors involved may include accumulation of plaque or 
calculus or the presence of foreign bodies, such as pos-
sible traces of dental cement or metal particles [2, 4, 19]. 
Burbano et  al. [37] reported the presence of five types 
of dental cement particles in biopsies of peri-implanti-
tis using scanning electron microscopy. Furthermore, 
Olmedo et  al. [24] reported that the presence of metal 
particles in the tissues plays a role in the corrosion pro-
cess of the metallic component of the implant. They pro-
posed that macrophages capture these metal particles, 
stimulating the release of cytokines, which play a role in 
bone resorption by activating osteoclasts and suppress-
ing osteoblast function, thereby reducing bone formation 
and promoting osteolysis. This deposit can occur during 
implant placement or due to the abutment connection 
[10, 20, 38]. Rodrigues et al. [39] supported this in a study 
that reported a PG and a PGCG associated with dental 
implants, and confirmed the presence of particles, pos-
sibly of titanium. However, the implant technique is com-
mon and there are few reference cases of PG and PGCG. 
This could possibly be influenced by the fact that some 
professionals surgically remove the peri-implant tis-
sues and do not send them for a histopathological study 
[13], or simply do not publish the cases. An interesting 
study, without conclusive results, found some differ-
ences in microvascular density, proliferative activity, and 
CD68 and Bcl-2 expression, between conventional and 
implant-associated granulomatous lesions [40]. In this 
study, histological and immunohistochemical aspects of 
peri-implant granulomatous lesions were analyzed and 
13 new cases were presented, 2 in men and 11 in women. 
Although this series is not included in this review due to 
the lack of individualized clinical data and not meeting 
our inclusion criteria, it is worth noting that the average 
age in this case series was 57.5 years, with a higher preva-
lence in women [2 of 13, 85%] and the posterior part of 
the mandible being the most affected area (10 of 13).
Peri-implantitis and marginal bone loss have been sug-
gested to expose the unpolished portion of the implant 
neck, which can cause chronic irritation to the adjacent 
mucosa and lead to the development of reactive lesions 
[2, 13, 20]. Data from the articles selected in this review 
suggest that peri-implant bone loss is more commonly 
associated with PGCG than PG (17:7). Several authors 
[11, 21, 41, 42] support this hypothesis. In addition, Hir-
shberg et al. [23] in their review of 25 peri-implant biopsy 
samples indicate that the PGCC around dental implants 
can causes loss of crestal bone that can eventually lead to 
implant failure. Surgical excision down to the bone level 
and aggressive curettage can cause additional bone loss 
around the implant [17, 19]. Furthermore, Hernández 
et al. [11] have also speculated whether bone loss is the 
cause or consequence of the granuloma and believe that 
the higher prevalence of these lesions in the posterior 
Table 3 Results of attributed etiopathogenesis
DOR: Deficient Oral Hygiene; Prosthesis‑PA‑PA: Prosthesis Poorly adapted with plaque accumulation; PD: Periodontal Disease; Exp: Explantation; No Exp: No 
explantation
(*) 3 are PG and 1 is PGCG; (#) 2 are PG; (&) 2 are PG and 1 PGCG; ($) 5 are PGCG; (@) It is a PGCG; (+) It is a PG; (++) They are PGCG 
Attributed etiopathogenesis
Bone graft DOH Prosthesis-PA-PA Trauma Adverse reaction to 
Warfarin
PD
4* 3& – – 1+ Exp
3# 3& 6$ 1@ ‑ 2++ No exp
7 6 6 1 1 2
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regions may be due to the greater bone loss that occurs 
due to the greater implant overload caused by the 
occlusal forces. Data from the selected articles suggest 
that peri-implant bone loss is more commonly associ-
ated with PGCG; in the present study, 10 of the 24 lesions 
with the presence of bone loss were severe and 8 of these 
lesions were PGCG [9].
Bischof et  al. [42] described a PGCG in a 56-year-old 
woman with three posterior mandibular implants. It 
seems that the angulation of the implants was inap-
propriate, which led to the healing abutments of two of 
them being poorly adjusted and juxtaposed. In addition, 
the patient reported the difficulty in cleaning the mouth, 
increasing the level of plaque in the area. This corrobo-
rates the study by Özden et al. [41], who described a case 
of PGCG associated with a dental implant that occurred 
due to a poorly fitted prosthesis, which led to the accu-
mulation of dental plaque and irritation of the gums. 
Regarding poorly designed prostheses, Bischof et  al. 
[42], Özden et al. [41], and Peñarrocha-Diago et al. [19] 
replaced the prostheses or temporarily removed it, which 
allowed better plaque control in these cases and the 
absence of recurrences. In our review, authors such as 
Bidra et al., Peñarrocha-Diago et al. and Baesso et al. [17, 
19, 33] included removal of the prosthesis and replace-
ment with a healing abutment, thus performing careful 
curettage and removal of the irritant factor; subsequently 
making a new prosthesis. We did not find justification 
in the literature to relate the appearance of the lesion to 
Warfarin medication, as suggested by Hirshberg et  al. 
[23].
Günhan et  al. [43] suggested that the appearance of 
these lesions could be due to the influence of sex hor-
mones, since multinucleated giant cells are a target 
for estrogens. Immunohistochemical investigation of 
estrogen receptors in PGCGs turned out positive. How-
ever, it can be suggested that in the context of implant-
associated PGCG, the hormonal influence would be less 
important, since most of the patients are postmenopausal 
and, therefore, serum estrogen levels are low [20]. Recur-
rences of PG and PGCG have been described, especially 
associated with teeth due to a hormonal imbalance dur-
ing pregnancy, especially in cases of PG [9, 33]. Scarano 
et  al. [35] article had as hypothesis that the multinucle-
ated cells present in central giant cell granuloma of the 
jawbones may simply represent a reactive component of 
the lesion and is a response to stimuli from the stroma. 
These cells have been shown to present a positivity to 
estrogen and to show a phenotype different from that of 
other giant cells found in sites of chronic inflammation 
and may be true osteoclasts.
The length of time between implant placement and ini-
tial presentation of PGCG and PG in our review ranged 
from 1 month to 12 years. Although there is controversy, 
since tooth extraction has been described as an etio-
logical factor for the development of PGCG, as demon-
strated by Hirshberg et  al. [23], who reported that the 
PGCG developed after tooth extraction in 8–11% of the 
cases examined, appearing up to one year after the proce-
dure. Scarano et al. [35] also indicate that the occurrence 
of OGCG may be related to teeth extraction carried out 
before the implant insertion, Given this, surgical removal 
must be done otherwise the affected implant will fail. 
Therefore, it would be interesting to investigate whether 
the cases shown in Table 1 underwent a dental extraction 
before implant placement and, if so, the time between 
extraction and implant placement. In this sense, only 
Bidra et  al. [17] and Peñarrocha-Diago et  al. [19] speci-
fied that the implants were placed post-extraction [20].
The recurrence rate of PGCG associated with teeth is 
varied, but it has been shown to range from 15 to 20% in 
most studies compared to PG that ranges from 0 to 16% 
[2]. In our review, the recurrence rate for PGCG and PG 
associated with implants was 34.4%. Therefore, it appears 
that the recurrence rate of these implant-associated 
lesions is higher than those unrelated to them [9, 19]. The 
reason for this difference in recurrence rates is unclear, 
but it could be due to difficulty faced in the removal of 
peri-implant tissues. However, curettage after excision 
does not seem to affect the recurrence rate, since the 
results are not significant [2, 13].
Several treatments for implant-associated PG and 
PGCG have been described, with conservative surgical 
extirpation with total removal of the lesion base and bone 
curettage being the treatment of choice [2, 9, 20]. Any 
irritating factors that may be causing or promoting the 
appearance of PGCG and PG must also be eliminated. 
Hernández et  al. [11] also recommend polishing the 
implant surface [19, 20]. Photodynamic therapy (PDT) 
has been used as a complementary treatment for peri-
implant diseases. Its main objective is controlling disease 
progression through decontamination of infected sur-
faces. PDT is a simple and non-invasive technique that 
has proven to have antibacterial effects. Although fur-
ther studies are needed to prove its efficiency in cases of 
PGCG around dental implants. [33]
Due to the aggressive nature of the lesion and the high 
recurrence rate, implants can fail unless the lesion is 
detected early and proper surgical removal is performed 
along with close follow-up. [23] The recommendation to 
remove an involved implant should be based on the clini-
cal judgment of the practitioner balanced with the risk 
of recurrence of the lesion due to potential inadequate 
removal if access is jeopardized by the continued physical 
presence of a dental implant. [21]
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The use of the Er-YAG, carbon dioxide or diode laser 
have been suggested as other treatment modalities and 
may offer advantages compared to conventional surgical 
techniques, especially by reducing the risk of postopera-
tive bleeding, pain, and edema and also by eliminating 
the need to suture at the end of the procedure [2, 9].
In the study of Kaya et al. [28], to avoid a peri-implant 
reactive lesion, they decontaminated the exposed implant 
surface using the Er:YAG laser. There was no scarring or 
recurrence at the 2-year follow-up. Hence, an Er:YAG 
laser appears to be a good therapeutic option for intraoral 
pyogenic granulomas.
As limitations we have found that the works are clinical 
cases and the longest series of cases found is 3 cases. In 
many cases the incidence and etiology are not well estab-
lished. Even in some reports the diagnosis is only clinical, 
which may represent an added bias. In some cases not all 
the data needed to perform the analysis is specified.
Conclusions
Implant-associated granulomas are more frequent in 
men, the mandible, and the most commonly diagnosed 
and referenced lesion is the PGCG.
The main focus of treatment is excision without tissue 
curettage with subsequent histopathological study. The 
lesions show a high recurrence rate that often require 
explantation, partly due to large bone loss or multiple 
recurrences. This recurrence rate is not affected by curet-
tage after excision.
Histopathological diagnosis is important, since if the 
result is a PGCG, the dentist will know that there is 
a higher risk of bone loss and a higher recurrence rate. 
Oral hygiene instructions and care by professionals in 
avoiding leaving "foreign" materials during treatment or 
rehabilitation should be considered in this entity. These 
conclusions should be interpreted with caution due to 
the low number of published cases.
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